FDA calls out Bristol Myers over cancer drug claims

(By Elizabeth Gregerson for Becker’s Hospital Review)

The FDA has accused pharmaceutical company Bristol Myers Squibb of making false or misleading claims about one of the company’s cancer drug, Krazati.

The agency’s accusations focus on Bristol Myers’ claims on its website about the drug’s’ efficacy and effect on survival, according to a letter dated Aug. 1 and sent to the company from the FDA’s Office of Prescription Drug Promotion. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.